M&A Deal Summary |
|
|---|---|
| Date | 2025-08-07 |
| Target | Scale Biosciences |
| Sector | Life Science |
| Buyer(s) | 10X Genomics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 1,306 |
| Revenue | 611M USD (2024) |
10X Genomics provides a genomics platform that upgrades the capabilities of existing short read sequencers. The Company does this through a combination of elegant microfluidics, chemistry, and bioinformatics. With the GemCode Platform, researchers can now find structural variants, haplotypes, and other valuable long range information while leveraging existing sequencing workflows. 10X Genomics was founded in 2012 and is based in Pleasanton, California.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-12-10 |
Spatial Transcriptomics
Stockholm, Sweden Spatial Transcriptomics offers technology that allows RNA sequencing to perform in 2D. Spatial Transcriptomics is based in Stockholm, Sweden. |
Buy | - |